Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) has earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $39.50.

A number of research analysts recently issued reports on the stock. BidaskClub downgraded shares of Biohaven Pharmaceutical Holding Co from a “buy” rating to a “hold” rating in a research report on Thursday. William Blair reiterated an “outperform” rating on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday. Morgan Stanley reiterated an “overweight” rating and set a $38.00 target price (down previously from $47.00) on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday. Piper Jaffray Companies reiterated a “buy” rating and set a $54.00 target price on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, September 12th. Finally, Zacks Investment Research upgraded shares of Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd.

Shares of Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) opened at 33.00 on Thursday. The stock’s 50 day moving average is $35.62 and its 200 day moving average is $27.71. The company’s market cap is $1.19 billion. Biohaven Pharmaceutical Holding Co has a 12 month low of $17.00 and a 12 month high of $39.51.

TRADEMARK VIOLATION WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Receives Average Recommendation of “Buy” from Brokerages” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/05/biohaven-pharmaceutical-holding-co-ltd-bhvn-receives-average-recommendation-of-buy-from-brokerages.html.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.